Investor Presentation November 2021
Quarter Ended Sep 30, 2021
Total revenue of $227.1 million, up 26% from $180.1 million for the prior-year period.
Net income attributable to ApolloMed of $34.3 million, up 105% from $16.7 million for the prior-year period.
Earnings per share – diluted of $0.74, up 64% from $0.45 per share for the prior-year period.
For complete information regarding our financials, see our periodic filings
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner.